Tech Company Financing Transactions
Kronos Bio Funding Round
Kronos Bio, operating out of San Mateo, secured $105 million from Vida Ventures and private investors.
Transaction Overview
Company Name
Announced On
7/19/2019
Transaction Type
Venture Equity
Amount
$105,000,000
Round
Series A
Investors
Vida Ventures (Lead Investor) (Stefan Vitorovic)
Proceeds Purpose
This Series A round of financing, supported by both legacy and new investors, exceeded its capital-raising goals based on the enthusiasm for the potential of the Kronos small molecule microarray (SMM) platform and the Kronos team to rapidly discover therapies for targets previously considered undruggable.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1300 So. El Camino Real 300
San Mateo, CA 94402
USA
San Mateo, CA 94402
USA
Phone
Undisclosed
Website
Email Address
Overview
Kronos Bio (Nasdaq: KRON) is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Norbert Bischofberger
Chief Financial Officer
Yasir Al-Wakeel
Chief Marketing Officer
Jorge DiMartino
Chief Operating Officer
Barbara Kosacz
Chief Scientific Officer
Christopher Dinsmore
Vice President
Christopher Lee
Vice President
Charles Lin
Vice President
Douglas Saffran
Vice President
Wes Trotter
VP - Bus. Development
Philip Gutry
VP - Operations
Zung To
VP - Regulatory Affairs
Jennifer Nicholson
Browse more venture capital transactions:
Prev: 7/19/2019: Nuvolo venture capital transaction
Next: 7/19/2019: N26 venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs